Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.

International journal of cancer - 1 Feb 2013

Seitz Hanna, Schmitt Markus, Böhmer Gerd, Kopp-Schneider Annette, Müller Martin

Abstract excerpt

The amino terminus of the human papillomavirus minor capsid protein L2 contains a major cross-neutralizing epitope that provides the basis for the development of a broadly protective HPV vaccine. This attainable broad protection would eliminate one of the major drawbacks of the commercial L1-based prophylactic vaccines. In this study, we asked whether there are natural variants of the L2 cross-neutralizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capsid

Share to Capsid Proteins

Share to Oncogene Proteins, Viral

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Papillomavirus Vaccines

Source

Identifiers

PMID: 22961598
DOI: 10.1002/ijc.27831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.PMID 22961598Read ↗

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Semantic proximity Read ↗

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read ↗

Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and ImmunogenicitySemantic proximity Read ↗

Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas.Semantic proximity Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.Semantic proximity Read ↗

In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccineSemantic proximity Read ↗

Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.Semantic proximity Read ↗

Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Semantic proximity Read ↗

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2Semantic proximity Read ↗

L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosisSemantic proximity Read ↗

HPV vaccine-induced cross-neutralising antibodies target complex epitopes on the major capsid proteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.